KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Halozyme Therapeutics (HALO) Accumulated Depreciation & Amortization (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Accumulated Depreciation & Amortization for 16 consecutive years, with $11.4 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 10.68% to $11.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.4 million through Dec 2025, up 10.68% year-over-year, with the annual reading at $11.4 million for FY2025, 10.68% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $11.4 million at Halozyme Therapeutics, up from $8.1 million in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was $11.4 million in Q4 2025, with the low at $700000.0 in Q1 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $4.9 million, with a median of $4.5 million recorded in 2022.
  • The sharpest move saw Accumulated Depreciation & Amortization tumbled 52.94% in 2021, then soared 457.14% in 2022.
  • Over 5 years, Accumulated Depreciation & Amortization stood at $3.0 million in 2021, then skyrocketed by 116.67% to $6.5 million in 2022, then surged by 70.77% to $11.1 million in 2023, then decreased by 7.21% to $10.3 million in 2024, then grew by 10.68% to $11.4 million in 2025.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $11.4 million, $8.1 million, and $5.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.